A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Bryan Oronsky, Carolyn M. Ray, Alexander I. Spira, Jane B. Trepel, Corey A. Carter, Hope M. Cottrill

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations


Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.

Original languageEnglish (US)
Article number103
JournalMedical Oncology
Issue number6
StatePublished - Jun 1 2017
Externally publishedYes


  • Epigenetic
  • Epithelial ovarian cancer
  • Platinum refractory
  • Platinum resistant
  • VEGF inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer'. Together they form a unique fingerprint.

Cite this